{"datasetJSONCreationDateTime":"2024-11-11T15:09:19","datasetJSONVersion":"1.1.0","fileOID":"www.cdisc.org/StudyMSGv2/1/Define-XML_2.1.0/2024-11-11/ti","dbLastModifiedDateTime":"2020-08-21T09:14:29","originator":"CDISC SDTM MSG Team","sourceSystem":{"name":"SAS on X64_10PRO","version":"9.0401M7"},"studyOID":"cdisc.com/CDISCPILOT01","metaDataVersionOID":"MDV.MSGv2.0.SDTMIG.3.3.SDTM.1.7","metaDataRef":"define.xml","itemGroupOID":"IG.TI","records":62,"name":"TI","label":"Trial Inclusion/Exclusion Criteria","columns":[{"itemOID":"IT.TI.STUDYID","name":"STUDYID","label":"Study Identifier","dataType":"string","length":12,"keySequence":1},{"itemOID":"IT.TI.DOMAIN","name":"DOMAIN","label":"Domain Abbreviation","dataType":"string","length":2},{"itemOID":"IT.TI.IETESTCD","name":"IETESTCD","label":"Incl/Excl Criterion Short Name","dataType":"string","length":7,"keySequence":2},{"itemOID":"IT.TI.IETEST","name":"IETEST","label":"Inclusion/Exclusion Criterion","dataType":"string","length":196},{"itemOID":"IT.TI.IECAT","name":"IECAT","label":"Inclusion/Exclusion Category","dataType":"string","length":9},{"itemOID":"IT.TI.TIVERS","name":"TIVERS","label":"Protocol Criteria Versions","dataType":"string","length":200,"keySequence":3}],"rows":[["CDISCPILOT01","TI","INCL01","Males and postmenopausal females at least 50 years of age.","INCLUSION","ORIGINAL"],["CDISCPILOT01","TI","INCL02","Diagnosis of probable AD as defined by NINCDS and the ADRDA guidelines.","INCLUSION","ORIGINAL"],["CDISCPILOT01","TI","INCL03","MMSE score of 10 to 23.","INCLUSION","ORIGINAL"],["CDISCPILOT01","TI","INCL04","Modified Hachinski Ischemic Scale score of <= 4.","INCLUSION","ORIGINAL"],["CDISCPILOT01","TI","INCL05","CNS imaging (CT scan or MRI of brain) compatible with AD within past 1 year. (See Protocol for incompatible findings.)","INCLUSION","ORIGINAL"],["CDISCPILOT01","TI","INCL06","Investigator has obtained informed consent signed by the patient (and/or legal representative) and by the caregiver.","INCLUSION","ORIGINAL"],["CDISCPILOT01","TI","INCL07","Geographic proximity to investigator's site that allows adequate follow-up.","INCLUSION","ORIGINAL"],["CDISCPILOT01","TI","INCL08","Caregiver will monitor administration of prescribed medications, and will be responsible for the overall care of the patient at home.","INCLUSION","ORIGINAL"],["CDISCPILOT01","TI","EXCL09","Persons who have previously completed or withdrawn from this study or any other investigating xanomeline TTS or the oral formulation of Zanomaline.","EXCLUSION","ORIGINAL"],["CDISCPILOT01","TI","EXCL10","Use of any investigational agent or approved Alzheimer's therapeutic medication within 30 days prior to enrollment into the study.","EXCLUSION","ORIGINAL"],["CDISCPILOT01","TI","EXCL11","Serious illness which required hospitalization within 3 months of screening.","EXCLUSION","ORIGINAL"],["CDISCPILOT01","TI","EXCL12","Diagnosis of serious neurological conditions (See Protocol)","EXCLUSION","ORIGINAL"],["CDISCPILOT01","TI","EXCL13","Episode of depression meeting DSM-IV criteria within 3 months of screening.","EXCLUSION","ORIGINAL"],["CDISCPILOT01","TI","EXCL14","A history within the last 5 years of the following: a) Schizophrenia b) Bipolar Disease c) Ethanol or psychoactive drug abuse or dependence.","EXCLUSION","ORIGINAL"],["CDISCPILOT01","TI","EXCL15","A history of syncope within the last 5 years.","EXCLUSION","ORIGINAL"],["CDISCPILOT01","TI","EXCL16","Evidence from ECG recording at screening of any of the following conditions: a) Left bundle branch block b) Bradycardia <50 beats per minute c) Sinus pauses >2 seconds (See Protocol for Remainder)","EXCLUSION","ORIGINAL"],["CDISCPILOT01","TI","EXCL17","A history within the last 5 years of a serious cardiovascular disorder, including a) Clinically significant arrhythmia (See Protocol for Remainder)","EXCLUSION","ORIGINAL"],["CDISCPILOT01","TI","EXCL18","A history within the last 5 years of a serious gastrointestinal disorder, including a) Chronic peptic/duodenal/gastric/esophageal ulcer that are untreated or refractory to treatment(See Protocol)","EXCLUSION","ORIGINAL"],["CDISCPILOT01","TI","EXCL19","A history within the last 5 years of a serious endocrine disorder, including a) Uncontrolled Insulin Dependent Diabetes Mellitus (IDDM) (See Protocol for other excluded disorders)","EXCLUSION","ORIGINAL"],["CDISCPILOT01","TI","EXCL20","A history within the last 5 years of a serious respiratory disorder, including a) Asthma with bronchospasm refractory to treatment b) Decompensated chronic obstructive pulmonary disease.","EXCLUSION","ORIGINAL"],["CDISCPILOT01","TI","EXCL21","A history within the last 5 years of a serious genitourinary disorder, including a) Renal failure b) Uncontrolled urinary retention","EXCLUSION","ORIGINAL"],["CDISCPILOT01","TI","EXCL22","A history within the last 5 years of a serious rheumatologic disorder, including a) Lupus b) Temporal arteritis c) Severe rheumatoid arthritis","EXCLUSION","ORIGINAL"],["CDISCPILOT01","TI","EXCL23","A known history of human immunodeficiency virus (HIV) within the last 5 years.","EXCLUSION","ORIGINAL"],["CDISCPILOT01","TI","EXCL24","A history within the last 5 years of a serious infectious disease including a) Neurosyphilis b) Meningitis c) Encephalitis","EXCLUSION","ORIGINAL"],["CDISCPILOT01","TI","EXCL25","A history within the last 5 years of a primary or recurrent malignant disease (See Exceptions in Protocol).","EXCLUSION","ORIGINAL"],["CDISCPILOT01","TI","EXCL26","Visual, hearing, or communication disabilities impairing the ability to participate in the study; (for example, inability to speak or understand English, illiteracy).","EXCLUSION","ORIGINAL"],["CDISCPILOT01","TI","EXCL27","Laboratory test values exceeding the Reference Range III for the patient's age in any of the following analytes: creatinine, total bilirubin, SGOT, SGPT, (See Protocol for Additional Analytes)","EXCLUSION","ORIGINAL"],["CDISCPILOT01","TI","EXCL28","Central laboratory test values below reference range for folate, and vitamin B12, and outside reference range for thyroid function tests.","EXCLUSION","ORIGINAL"],["CDISCPILOT01","TI","EXCL29","Positive syphilis screening with confirmatory testing.","EXCLUSION","ORIGINAL"],["CDISCPILOT01","TI","EXCL30","Central laboratory test value above reference range for glycosylated hemoglobin (A1C) (insulin dependent diabetes mellitus patients only).","EXCLUSION","ORIGINAL"],["CDISCPILOT01","TI","EXCL31","Treatment with medications within 1 month prior to enrollment (See Protocol)","EXCLUSION","ORIGINAL"],["CDISCPILOT01","TI","INCL01","Males and postmenopausal females at least 50 years of age.","INCLUSION","AMENDMENT 1"],["CDISCPILOT01","TI","INCL02","Diagnosis of probable AD as defined by NINCDS and the ADRDA guidelines.","INCLUSION","AMENDMENT 1"],["CDISCPILOT01","TI","INCL03","MMSE score of 10 to 23.","INCLUSION","AMENDMENT 1"],["CDISCPILOT01","TI","INCL04","Modified Hachinski Ischemic Scale score of <= 4.","INCLUSION","AMENDMENT 1"],["CDISCPILOT01","TI","INCL05","CNS imaging (CT scan or MRI of brain) compatible with AD within past 1 year. (See Protocol for incompatible findings.)","INCLUSION","AMENDMENT 1"],["CDISCPILOT01","TI","INCL06","Investigator has obtained informed consent signed by the patient (and/or legal representative) and by the caregiver.","INCLUSION","AMENDMENT 1"],["CDISCPILOT01","TI","INCL07","Geographic proximity to investigator's site that allows adequate follow-up.","INCLUSION","AMENDMENT 1"],["CDISCPILOT01","TI","INCL08","Caregiver will monitor administration of prescribed medications, and will be responsible for the overall care of the patient at home.","INCLUSION","AMENDMENT 1"],["CDISCPILOT01","TI","EXCL09","Persons who have previously completed or withdrawn from this study or any other investigating xanomeline TTS or the oral formulation of Zanomaline.","EXCLUSION","AMENDMENT 1"],["CDISCPILOT01","TI","EXCL10","Use of any investigational agent or approved Alzheimer's therapeutic medication within 30 days prior to enrollment into the study.","EXCLUSION","AMENDMENT 1"],["CDISCPILOT01","TI","EXCL11","Serious illness which required hospitalization within 3 months of screening.","EXCLUSION","AMENDMENT 1"],["CDISCPILOT01","TI","EXCL12A","Diagnosis of serious neurological conditions (See Amendment 1)","EXCLUSION","AMENDMENT 1"],["CDISCPILOT01","TI","EXCL13","Episode of depression meeting DSM-IV criteria within 3 months of screening.","EXCLUSION","AMENDMENT 1"],["CDISCPILOT01","TI","EXCL14","A history within the last 5 years of the following: a) Schizophrenia b) Bipolar Disease c) Ethanol or psychoactive drug abuse or dependence.","EXCLUSION","AMENDMENT 1"],["CDISCPILOT01","TI","EXCL15","A history of syncope within the last 5 years.","EXCLUSION","AMENDMENT 1"],["CDISCPILOT01","TI","EXCL16","Evidence from ECG recording at screening of any of the following conditions: a) Left bundle branch block b) Bradycardia <50 beats per minute c) Sinus pauses >2 seconds (See Protocol for Remainder)","EXCLUSION","AMENDMENT 1"],["CDISCPILOT01","TI","EXCL17","A history within the last 5 years of a serious cardiovascular disorder, including a) Clinically significant arrhythmia (See Protocol for Remainder)","EXCLUSION","AMENDMENT 1"],["CDISCPILOT01","TI","EXCL18","A history within the last 5 years of a serious gastrointestinal disorder, including a) Chronic peptic/duodenal/gastric/esophageal ulcer that are untreated or refractory to treatment(See Protocol)","EXCLUSION","AMENDMENT 1"],["CDISCPILOT01","TI","EXCL19","A history within the last 5 years of a serious endocrine disorder, including a) Uncontrolled Insulin Dependent Diabetes Mellitus (IDDM) (See Protocol for other excluded disorders)","EXCLUSION","AMENDMENT 1"],["CDISCPILOT01","TI","EXCL20","A history within the last 5 years of a serious respiratory disorder, including a) Asthma with bronchospasm refractory to treatment b) Decompensated chronic obstructive pulmonary disease.","EXCLUSION","AMENDMENT 1"],["CDISCPILOT01","TI","EXCL21","A history within the last 5 years of a serious genitourinary disorder, including a) Renal failure b) Uncontrolled urinary retention","EXCLUSION","AMENDMENT 1"],["CDISCPILOT01","TI","EXCL22","A history within the last 5 years of a serious rheumatologic disorder, including a) Lupus b) Temporal arteritis c) Severe rheumatoid arthritis","EXCLUSION","AMENDMENT 1"],["CDISCPILOT01","TI","EXCL23","A known history of human immunodeficiency virus (HIV) within the last 5 years.","EXCLUSION","AMENDMENT 1"],["CDISCPILOT01","TI","EXCL24","A history within the last 5 years of a serious infectious disease including a) Neurosyphilis b) Meningitis c) Encephalitis","EXCLUSION","AMENDMENT 1"],["CDISCPILOT01","TI","EXCL25","A history within the last 5 years of a primary or recurrent malignant disease (See Exceptions in Protocol).","EXCLUSION","AMENDMENT 1"],["CDISCPILOT01","TI","EXCL26","Visual, hearing, or communication disabilities impairing the ability to participate in the study; (for example, inability to speak or understand English, illiteracy).","EXCLUSION","AMENDMENT 1"],["CDISCPILOT01","TI","EXCL27","Laboratory test values exceeding the Reference Range III for the patient's age in any of the following analytes: creatinine, total bilirubin, SGOT, SGPT, (See Protocol for Additional Analytes)","EXCLUSION","AMENDMENT 1"],["CDISCPILOT01","TI","EXCL28","Central laboratory test values below reference range for folate, and vitamin B12, and outside reference range for thyroid function tests.","EXCLUSION","AMENDMENT 1"],["CDISCPILOT01","TI","EXCL29","Positive syphilis screening with confirmatory testing.","EXCLUSION","AMENDMENT 1"],["CDISCPILOT01","TI","EXCL30","Central laboratory test value above reference range for glycosylated hemoglobin (A1C) (insulin dependent diabetes mellitus patients only).","EXCLUSION","AMENDMENT 1"],["CDISCPILOT01","TI","EXCL31A","Treatment with medications within 1 month prior to enrollment a) Anticonvulsants b) Alpha receptor blockers c) Calcium channel blockers that are CNS active (See Amendment 1)","EXCLUSION","AMENDMENT 1"]]}